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Abstract Oxidized PLs (OxPLs) generated in health and
disease are now recognized as important mediators of cel-
lular signalling. There is an increasing body of evidence
showing that PL peroxidation is not only increased in vas-
cular disorders, but is also a physiological event of rele-
vance to coagulation, innate immunity, and self-tolerance.
Nonenzymatically formed OxPLs generated during chronic
inflammation is an uncontrolled event, generating hundreds
of diverse structures, and prone to more deleterious bio-
activities. In contrast, enzymatic formation of OxPLs is
tightly regulated, involving receptors and intracellular sig-
naling, acting as part of the normal physiological response
to injury in order to restore homeostasis. In the present
review, the major nonenzymatic OxPLs structures found
during vascular inflammation are summarized, along with
a brief description of their known biological activities. Also,
we review what is currently known about enzymatic forma-
tion of OxPLs by acutely activated immune cells and their
signaling actions under homeostatic and pathological
conditions.
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Introduction
Phospholipids (PLs) are the major components of cell mem-
branes and play a crucial role in the biochemistry of all
living cells. They provide a permeable barrier as well as
acting as substrates for the synthesis of essential signalling
mediators such as eicosanoids. PLs consist of a glycerol
backbone connected to two nonpolar fatty acids at sn1 and
sn2 and a phosphate-containing polar headgroup at the sn3
position. In mammalian cells, polyunsaturated fatty acids
are usually bound to the sn2 of glycerol where the majority
of oxidation will occur. Oxidation of esterified polyunsatu-
rated fatty acids can be initiated via both enzymatic and
nonenzymatic mechanisms, and can form hundreds of di-
verse structures [1••, 2]. Phosphatidylcholine (PC) is the most
abundant PL species in eukaryotic cell membranes (40–50 %)
and, as a result, the vast proportion of nonenzymatically-
formed OxPLs detected in mammalian tissues contain the
choline headgroup. In contrast, phosphatidylethanolamine
(PE) is the prominent PL class modified via enzymatic
oxidation [3-7].
OxPLs exhibit a vast range of biological activities,
including acting as markers of “modified-self” that can
induce apoptotic and senescent cell removal, and more
complex interactions, such as regulation of immune re-
sponses [1••, 2]. Their involvement in activation of
platelet aggregation and monocyte adhesion, as well as sup-
pression of cytokine generation and neutrophil superoxide
release has been reported [8–12]. Also, they can act as both
pro- and anti-inflammatory mediators during the progression
of atherosclerosis.
Nonenzymatically oxidized PLs that derive from PL hy-
droperoxide decomposition have been measured in athero-
sclerotic lesions of humans and other mammalian models of
atherosclerosis [1••, 13–17]. LC-MS analysis of human
atheroma at different stages of development identified sim-
ilar OxPL species at different stages of the disease [18]. The
detection of early oxidation species, like hydroperoxides
and further oxidized products such as fragmented OxPLs,
suggests that during the development of atherosclerotic le-
sions, nonenzymatically formed OxPLs are continuously
being formed through hydroperoxide decomposition. Even
though this is expected to be an uncontrolled event, whether
the initial hydroperoxides originate from oxidation reactions
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driven by enzymatic or nonenzymatic processes in vivo
remain unknown.
Enzymatically formed OxPLs are generated by proteins
that are conserved among all mammalian species, such as
lipoxygenases (LOX) and cyclooxygenases (COX), and
their synthesis involves receptors and intracellular signalling
pathways [1••, 19••]. Tight control of this process and asso-
ciated biological actions of the products observed in vitro,
indicates that these lipids are of physiological importance
and likely to play a role in innate immune defences and
haemostasis (see below). In contrast, nonenzymatic oxi-
dized PLs are generated in diseases characterized by chronic
inflammation, such as atherosclerosis, where the enhanced
production of free radicals, as a result of immune cells
activation, leads to uncontrolled oxidant toxicity. In both
circumstances, common bioactivities are displayed with
both classes likely being important in human health and
disease.
In this review, we summarise the major nonenzymatic
OxPL structures found during vascular inflammation and
we give a brief description of their known biological activ-
ities. Then, we focus on what is known about enzymatic
formation of OxPLs generated by acutely activated immune
cells and their signaling actions in health and disease.
Nonenzymatic Formation of Oxidized PLs
Atherosclerosis is a chronic vascular disorder characterized
by an accumulation of lipids in the artery wall and persistent
inflammation [20•]. The initiation and progression of the
disease is controlled by inflammatory molecular and cellular
mediators, which often trigger oxidative damage to biolog-
ical molecules. Enhanced production of free radicals includ-
ing reactive oxygen species (ROS) generated by activated
phagocytes results in increased levels of OxPLs, which have
been detected in human atherosclerotic lesions [13, 21].
Nonenzymatic formation of oxidized PLs is regulated by
chemical reaction mechanisms that are propagated by either
nonradical reactive oxygen species (ROS) or free radicals.
Depending on the reactive oxygen species and the nature of
the lipid target, both nonradical ROS and free radicals can
generate a diverse range of lipid structures without enzy-
matic regulation [22, 23]. However, how this form of oxi-
dation is initiated is currently unknown and could include
either enzymatic or nonenzymatic mechanisms.
Relevant nonenzymatic oxidative modifications to PLs in
terms of inflammatory cell biology rely greatly on the nature
of the oxidant species, such as those mediated by ROS like
nitrogen dioxide (•NO2), nitric oxide, superoxide, hydrogen
peroxide, hydroxyl radical (•OH) hypochlorite (HOCl), and
singlet O2 [24, 25]. These are often generated by activated
phagocytes during chronic inflammation. In addition, reac-
tive oxygen species such as oxides of nitrogen and reactive
aldehydes can similarly originate from multiple exogenous
sources, including air pollution, environment, smoking, UV
light, or ionizing radiation.
Inorganic radical species such as •OH and •NO2 can react
with various unsaturated lipids, leading to the formation of
isoprostanes, oxidized cholesterol, and other lipid species
[26, 27]. PLs containing polyunsaturated fatty acids are very
susceptible to peroxidation by reactive oxygen species due
to the presence of bisallylic methylene groups between
double bonds. Hence, hydrogens become more susceptible
to abstraction in PLs containing these lipids. The initial
reaction of inorganic radicals with polyunsaturated fatty
acids involves hydrogen abstractions of the bisallylic hydro-
gens, followed by rearrangement of double bonds and addi-
tion of oxygen, which leads to highly reactive peroxyl
radicals and subsequently formation of hydroperoxides
[1••]. Also, Fenton-like reactions, where lipid peroxyl or
alkoxyl radicals are produced by decomposition of pre-
formed lipid hydroperoxides can act as the initial mecha-
nism of PL oxidation [28].
Following the initiation step, the resulting peroxyl
radicals or hydroperoxides then can propagate forming
secondary peroxidation products through a variety of
mechanisms, without participation of enzymes. The three major
pathways involve (1) cyclization, rearrangement, and further
oxidation reactions via the isoprostane pathways (e.g.,
isoprostanes, isolevuglandins, and isothromboxanes); (2) hydro-
peroxide fragmentation generating shortened fatty acid residues
[e.g., oxidatively truncated (un)saturated PLs]; (3) additional
oxidation (e.g., dihydroxy-PC and epoxy-monohydroxy-PC)
[1••].
During vascular inflammation LDL molecules accumu-
lated within the subendothelial space undergo oxidative
modification, resulting in the formation of mildly modified
LDL (MM-LDL) and oxidized LDL (ox-LDL). 1-Palmitoyl-
2-arachidonoyl-sn-glycero-3-phosphorylcholine (PAPC), a
naturally occurring PL found in cell membranes, is one the
main PLs present in MM-LDL. Oxidation of PAPC induced
by free radicals results in formation of a range of products,
including fragmented (e.g., truncated PLs) and nonfragmented
OxPLs (e.g., isoprostanes, levuglandins, isofurans, and
isothromboxanes), which are described in the following
sections.
Fragmented OxPLs
Fragmented OxPLs are generated via oxidative fragmenta-
tion of hydroperoxides, followed by transformation of
peroxides/peroxyls into advanced oxidation products [1••].
Oxidative fragmentation of peroxyl radicals forms truncated
PLs such as PAPC-derived truncated oxidized products, 1-
palmytoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphocholine
(POVPC), 1-palmitoyl-2-glutaroyl-sn-glycero-3-
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phosphocholine (PGPC), 5-keto-6-octendioic acid ester of
2-lyso-phosphocholine (KOdiA-PC), 5-hydroxy-8-oxo-6-
octenedioic acid ester of 2-lysophosphocholine (HOdiA-
PC), 1-palmitoyl-2-(5-hydroxy-8-oxooct-6-enoyl)-sn-
glycero-3-phosphocholine (HOOA-PC) and 5-keto-8-oxo-
6-octenoic acid esters of 2- lysophosphocholine (KOOA-
PC), which have been found at high concentrations within
fatty streaks of cholesterol-fed rabbits and hyperlipidemic
mice [16, 17]. Quantification of POVPC and PGPC in
aortae of cholesterol-fed rabbits demonstrated approximate-
ly 60 μg/g and 45 μg/g of wet tissue weight, respectively
[17]. In lesions of cholesterol-fed rabbits these levels were
even higher, approximately 100 μg/g of POVPC and
60 μg/g of wet tissue weight in PGPC [13].
Oxidative cleavage of PAPC forms POVPC, which can
be further oxidized to PGPC. Although POVPC and PGPC
are of similar chemical structure they mediate distinct activ-
ities—for instance, POVPC enhances neutrophil binding to
endothelial cells, while PGPC inhibits [11]. A recent study
using gene expression analysis has shown that OxPAPC,
accumulated in atherosclerotic lesions, is proatherogenic
and regulates the expression of more than a thousand genes
in human aortic endothelial cells [29]. POVPC and PGPC
have multiple effects on different cell types, including reg-
ulation of inflammatory functions of endothelial cells, inhi-
bition of macrophage ox-LDL uptake, induction of
apoptotic pathways in vascular smooth muscle cells, in-
creased monocyte synthesis of chemotactic factors, and
enhanced surface expression of adhesion molecules on en-
dothelial cells [1••, 11, 13, 30–34]. In addition, KOdiA-PC,
HOdiA-PC, HOOA-PC, and KOOA-PC formed from frag-
mentation of hydroperoxide-derived dienes can act as li-
gands for the scavenger receptor CD36 [16]. HOOA-PC
induces proinflammatory activities by promoting monocyte
access to chronic lesions, as seen in atherosclerosis, via
endothelial cell/monocyte binding and increasing chemo-
kine (MCP-I and IL-8) levels [35].
Non-Fragmented OxPLs
Isoprostanes are prostaglandin-like compounds formed in
situ in cell membranes via free radical–mediated peroxida-
tion of polyunsaturated fatty acids, mainly arachidonic acid
[1••]. The side chains of these molecules are almost exclu-
sively oriented cis to the cyclopentane ring with several
possible regioisomers yielding a large variety of structures.
Unlike prostaglandins, isoprostane synthesis is believed to
occur independently of cyclooxygenases. Their formation is
initiated via peroxidation of arachidonic acid induced by
free radicals, generating arachidonyl radicals containing
two molecules of oxygen [36, 37].
Nonregioselective abstraction of hydrogen atoms from
arachidonic acid forms three regioisomeric pentadienyl
radicals which react with oxygen molecules, generating four
PGH2-like intermediates. The bicyclic endoperoxide inter-
mediates are subsequently reduced to form PGF2-like com-
pounds or go through various rearrangements to form
isothromboxanes and other oxidized lipids [2].
Differently to prostaglandins that result from enzymatic
oxidation of free arachidonic acid, isoprostanes are thought
to be primarily generated via nonenzymatic oxidation of PL-
esterified arachidonic acid [38]. Esterified isoprostanes are
then released as free acids by either phospholipase A2 or
platelet-activating factor acetylhydrolase activity, into the
circulation. Eight-epi PGF2α and IPF2α-I are examples of
isoprostanes found at high concentration in human athero-
sclerotic lesions, localized intracellularly, predominantly in
macrophage-rich areas [39].
Separate to the transformation of bicyclic endoperoxides,
is formation of 1-palmitoyl-2-(5,6-epoxyisoprostane E2)-sn-
glycero-3-phosphocholine (PEIPC). This oxidised PL is
formed through free radical oxidation and cyclization of
the arachidonic acid group of PAPC, followed by dehydra-
tion of the isoPGG2-PC to produce epoxyisoprostane-PLs
[40]. Further dehydration of the cyclic isoprostane ring of
PEIPC generates 1-hexadecanoyl-2-(5,6-epoxyisoprostane
A2 oyl)-snglycero-3 phosphocholine (PECPC). PEIPC
was detected at high levels in atherosclerotic lesions of
cholesterol-fed rabbits, 60–100 μg/g of wet tissue weight
[13, 16]. PEIPC and PECPC are potent activators of endo-
thelial cells, increasing synthesis of IL-8 and MCP-1,
and are also concentrated within atherosclerotic lesions
[10, 11, 31, 41].
Another example of nonfragmented OxPLs are esterified
isolevuglandins formed via rearrangement of isoPGH2-PC,
which differ from isoprostanes by containing aldehyde groups,
making them extremely reactive toward amine-containing
molecules, such as proteins. Hence, isolevuglandins have been
found as protein adducts in vivo. They are detected in plasma
at significantly higher levels compared to isoprostanes and,
considering that many proteins have half-lives varying from
days to weeks, isolevuglandin-protein adducts can accu-
mulate over time and possibly be used to assess oxidative
stress status in vivo [42]. For example, Poliakov and co-
workers reported highly elevated isolevuglandins levels in
plasma in individuals with atherosclerosis compared to
controls [42].
Similarly to isoprostanes, isofurans are nonenzymatically
formed but contain a substituted tetrahydrofuran ring. High
oxygen concentrations favour isofuran over isoprostane for-
mation. Hence, production of isofurans is differentially
modulated by oxygen levels [43]. Due to their stability,
esterified isofurans can be used as an index of lipid
oxidation.
Last, PGH2-like bicyclic endoperoxide intermediates can
be transformed through spontaneous rearrangement into
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esterified isothromboxane A2, which is very unstable and is
rapidly hydrolysed into isothromboxane B2.
Enzymatic Formation of Oxidized PLs
Enzymatic formation of oxidized PLs is mediated either by
direct PL oxidation or esterification of preformed oxidized
fatty acids into PLs. During immune cell activation, OxPLs
can be formed via lipoxygenase (LOX) or cyclooxygenase
(COX) on both esterified and free polyunsaturated fatty acids
[44, 45]. For instance, phospholipase A2 (PLA2) hydrolyses
PLs at sn2, generating arachidonate for LOX and COX enzy-
matic oxidation, forming hydroxyeicosatetraenoic acids
(HETEs) and PGH2, respectively [44]. PGH2 then undergoes
further enzymatic metabolism to formmore stable compounds
such as prostaglandin E2 (PGE2), PGD2 and thromboxane B2
(TXB2). Over the last 6–7 years, it has been observed that
oxidized fatty acids like 12-HETE and 15-HETE, and also
PGE2, are not only acutely generated as free acids but also as
larger PL esterified species with distinct biological and phys-
ical properties. These lipids are described in detail in the
following sections.
Oxidized PLs Generated by Human Monocytes and Murine
Macrophages
Human peripheral monocytes express high levels of the 15-
LOX isoform that generates 15-HETE, in response to Th2
cytokines. Similarly, naïve murine peritoneal macrophages
express the functional equivalent 12/15-LOX, which gener-
ates primarily 12-HETE. The enzyme is constitutively ac-
tive under basal conditions in both human monocytes and
murine macrophages, but can be further activated using
ionophore [46].
The Th2 cytokines IL-4 and IL-13 are known to contrib-
ute to severity of asthma and lung allergy by inducing
ciliated epithelial cell differentiation into mucus producing
goblet cells. Studies have shown that IL-4 and IL-13 induce
high levels of 15-LOX expression in human asthmatic epi-
thelial cells [47–50]. Zhao and coworkers have reported that
human bronchial epithelial cells, in culture with IL-13-
stimulated 15-LOX expression, generate two 15-HETE-
PEs, which can enhance expression of MUC5AC, a gene
associated with hypersecretion of mucus in asthma [51].
Moreover, in human bronchial epithelial cells, IL-13 in-
duced 15-LOX and its product 15-HETE-PE to bind to
PE-binding protein-1, causing its dissociation from Raf-1
and allowing the activation of ERK [52].
More recently, Uderhardt and colleagues showed that
OxPLs on the surface of resident peritoneal macrophages
serve as binding sites for soluble receptors for apoptotic
cells. In this study, 12/15-LOX–expressing resident perito-
neal macrophages were reported as responsible for
noninflammatory clearance of apoptotic cells and inhibiting
their uptake by freshly recruited inflammatory monocytes
during inflammation [53••]. Oxidized PE was found to
mediate these effects through binding MFG-E8, suggesting
that 12/15-LOX enzyme is the major factor orchestrating the
regulation of apoptotic cell clearance and preservation of
immunologic tolerance [53••].
We previously identified a family of four esterified
15-HETEs, comprising one diacyl (18:0a/15-HETE-PE)
and three plasmalogen PE species (18:0p, 18:1p,
16:0p/15-HETE-PE) generated equally in human periph-
eral monocytes and by murine resident macrophages,
both basally, and on activation with calcium ionophore
[54]. Without activation, human monocytes already gen-
erate basal levels of HETE-PEs, 0.5–3 ng/106 mono-
cytes. These levels approximately double on ionophore
activation (~7 ng/106 monocytes), suggesting that the
LOX enzyme is already constitutively active, generating
HETE-PEs without inflammatory stimulation and that
the PE-esterified HETEs are executing homeostatic
functions [3, 54]. In contrast to free 15-HETE, these
products remain cell associated, suggesting an autocrine
mode of action. The predominance of the 15S-HETE
enantiomer was demonstrated by MS/MS and chiral
chromatography, confirming their enzymatic generation.
In addition, consistent with the already known ability of
the 15-LOX isoform to directly oxidize PLs, stable
isotope labelling studies revealed that HETE-PEs are
formed by direct oxidation of the intact PE by 15-
LOX enzyme, with no requirement for hydrolysis of
arachidonate by phospholipases [3, 54]. They corre-
spond to approximately 30 % of the total 15-HETE
generated [3].
More recently, two additional families of related lipids have
been identified in human IL-4 monocytes and murine perito-
neal macrophages—specifically, hydroperoxyeicosatetraenoic
acid (HpETE) and ketoeicosatetraenoic acids (KETE) attached
to PE [4••]. As for HETE-PEs, they contain positional isomers
matching cellular LOX isoform expression, with 15- and 12-
isomers detected in human or murine cells, respectively. Using
LC/MS/MS, the PEs attached to KETEs were identified as
18:0a, 18:0p, 18:1p and 16:0p, where one is acyl-linked and
three are plasmalogen-linked at sn1. Although their amounts
are lower compared to HETE-PEs (478 pg/2x106 mono-
cytes) they are also formed on ionophore activation, and are
absent in macrophages from 12/15-LOX deficient mice.
Consistent with previous reports showing that 12/15-
LOX-/- macrophages are incapable of mounting a normal
phagocytic response in vitro [55], we recently observed that
they contain larger numbers of cytoplasmic vesicles and
anomalous mitochondria, which may allow speculation about
defective autophagy or exosomal processing (V. Hammond
and V.B.O., unpublished data, 2012).
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We propose that HpETE-PEs are first formed by LOX
enzyme, subsequently reduced to HETE-PEs by cellular
glutathione peroxidises, and finally HETE-PEs are oxidized
by prostaglandin dehydrogenase (PGDH) to KETE-PEs,
which remain cell-associated. Experiments using H2
18O
and a 15-PGDH inhibitor suggest that 15-KETE-PEs may
form through direct oxidation of preformed HETE-PE by
the enzyme, rather than esterification of newly generated
KETE.
In terms of biological function, both 15-HETE-PE
and 15-KETE-PE dose dependently activate PPARγ
transcriptional activity in macrophages. It is speculated
that these lipids may act indirectly, either through PLA2
hydrolysis to release free PPARγ ligands, or via up-
stream modulation of PPARγ expression [4••]. 15-
HETE-PE can attenuate inflammatory signalling through
TLR4 inhibition, a known inhibitor of PPARγ expres-
sion and activity [3, 56]. In this way, dampening down
TLR4 via CD14 and LPS-binding protein may result in ele-
vated PPARγ signalling. These findings are consistent with
previous reports showing that oxidized free fatty acid gener-
ated by LOXs can activate PPARγ [57]. Figure 1 shows the
chemical structures of 15-HETE-PEs and 15-KETE-PEs gen-
erated by activated human monocytes and their known bio-
logical actions.
Thus, new families of bioactive mediators from the
12/15-LOX pathway, as described above, may contribute
to its known anti-inflammatory actions in vivo and
maybe of potential therapeutic benefit in treating chron-
ic inflammation.
Oxidized PLs Generated by Human Platelets
The contribution of platelets to atherosclerosis has been firmly
established over the years. Human platelets express two dif-
ferent enzymes that are known to play a role in PL oxidation, a
platelet-specific 12-LOX isoform and COX-1. 12-HETE is
the most abundant eicosanoid generated by agonist-activated
platelets, but it does not appear to directly regulate platelet
function [58]. In contrast, platelet COX-1-derived thrombox-
ane is well known to induce platelet aggregation via the
thromboxane receptor and also act as a potent vasoconstrictor
[59]. Both enzymes are activated acutely during agonist plate-
let activation (thrombin, collagen) in a calcium-dependent
manner.
We recently showed that agonist-activated human plate-
lets generate six molecular species of esterified 12-HETE,
comprising four PEs (16:0p, 18:1p, 18:0p and 18:0a/12-
HETE-PE) and two PCs (16:0a, 18:0a/12-HETE-PC) via
12-LOX [5••]. Moreover, esterified 12-HETEs are not gen-
erated by platelets from 12-LOX-/- mice (M. Aldrovandi and
V.B.O., unpublished data, 2012). The lipids are formed
within 5 min of activation by thrombin, collagen or iono-
phore, with levels of 12-HETE-PEs reaching~6 ng/4x107
platelets and 12-HETE-PC~18 ng/4x107 platelets. 12-
HETE-PEs and 12-HETE-PC generation is triggered by
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activation of protease activated receptors 1 and 4 (PARs).
Several intracellular signalling mediators are required, in-
cluding Ca2+, src tyrosine kinases, protein kinase C, and
sPLA2. Esterified 12-HETEs account for approximately
one-third of the total 12-HETE produced. Stable isotope
labelling studies showed that 12-HETE-PEs are formed by
esterification of preformed 12-HETE, instead of direct
PL oxidation [5••]. Esterified 12-HETEs remain predom-
inantly membrane associated, with a proportion of the
HETE-PEs trafficking to the outside of the plasma
membrane. In accordance with previous observations show-
ing that nonenzymatically oxidised PLs can be procoagulant,
esterified 12-HETEs can promote thrombin generation in vitro
[60, 61].
Activated human platelets also generate several addition-
al PL-esterified hydroxy-fatty acids via 12-lipoxygenase,
where the 12-HETE is replaced by 12-LOX-oxidized
docosahexaenoic acid (DHA)-containing PE. The products
comprise 4 PE-esterified hydroxydocosa-hexaenoic acids
(HDOHE-PE), two diacyl (16:0a, 18:0a) and two
plasmalogen (16:0p, 18:0p), containing predominantly the
14-HDOHE positional isomer [6•]. They form acutely in the
presence of thrombin in a calcium-dependent manner, with
levels up to 2–4 ng/4x107 platelets. Studies using recombi-
nant human 12-LOX and cPLA2 inhibitors demonstrate that
formation of HDOHE-PEs occurs via PLA2 hydrolysis of
DHA, followed by 12-LOX oxidation and re-esterification
of free 14-HDOHE into PLs [6•].
Interestingly, we recently identified COX-1–derived PE
esterified PGE2 and PGD2, which are formed within 2–
5 min of platelet activation by thrombin, collagen or iono-
phore in a calcium dependent manner (M. Aldrovandi and
V.B.O., unpublished data, 2012). Their functions remain
unknown and generation of PL-esterified prostaglandins in
COX-2 expressing cells have not yet been studied. Never-
theless, since synthesis of glyceryl-PGE2/D2 in response to
lipopolysaccharide by macrophages expressing the induc-
ible COX-2 isoform have already been shown, it is also
likely that PL-esterified prostaglandins are generated in
COX-2–expressing cells [62–64].
Oxidized PLs Generated by Human Neutrophils
Neutrophils are the most abundant white cells in the circu-
lation and until recently, received little attention for their
role in the pathophysiology of atherosclerosis. Nevertheless,
studies have provided convincing evidence for the presence
of these cells in atherosclerotic plaques [65, 66]. Neutrophils
express the 5-LOX isoform, which, upon activation, gener-
ates 5-HpETE through oxygenation of arachidonic acid. 5-
HpETE can undergo further processing to 5-HETE, 5-oxo-
ETE and the potent chemoattractant leukotriene B4. Recent-
ly, we reported that primary human neutrophils acutely
generate four 5-LOX–derived lipids, comprising
plasmalogen and diacyl PL esterified 5-HETEs, in response
to bacterial peptides, chemokines, and chemical stimuli,
such as phorbol and calcium ionophore [7••]. Four are
generated: 16:0a/5-HETE-PC, 18:0p/5-HETE-PE, 18:1p/5-
HETE-PE, and 16:0p/5-HETE-PE. Upon agonist activation,
they form within 2 min with total 5-HETE-PLs reaching up
to 0.37 ng/106 neutrophils. As with platelets, esterified 5-
HETEs are generated by fast esterification of newly formed
free 5-HETE, remaining cell associated and localized to
nuclear and extranuclear membrane. They are synthesised
via a highly coordinated mechanism, involving receptors
and intracellular signalling intermediates, including
Ca2+, PLC, cPLA2, sPLA2, mitogen-activated protein
kinase/extracellular signal-regulated kinase 1, and 5-LOX
activating protein (FLAP). The 5-HETE-PEs regulate a
number of neutrophil activities in vitro, including enhanc-
ing superoxide and inhibiting neutrophil extracellular trap
(NET) release [7••].
Conclusion
OxPLs formed either enzymatically or nonenzymatically are
known to have multiple effects on different cell types of
relevance to health and inflammatory vascular disease. Sev-
eral nonenzymatically OxPLs have been identified in ath-
erosclerotic lesions, affecting macrophages, endothelial
cells and other cell types, contributing to the initiation and
development of the disease.
Over the past few years, it has become clear that OxPLs
are important not only during chronic inflammation but also
in maintaining homeostasis. In particular, a number of new
families of OxPLs enzymatically generated by acutely acti-
vated cells have been identified. Their formation is tightly
regulated and they remain cell associated, suggesting a
paracrine mechanism of action, possibly mediated at or
close to the plasma membrane. The great majority of ester-
ified PLs identified in our laboratory are synthesized via
LOXs. Nevertheless, in contrast to the idea that prostaglan-
dins are found exclusively as unesterified lipids, we have
also observed acute formation of esterified PGE2/D2-PEs via
the constitutively expressed COX-1 isoform, in thrombin
activated platelets.
It is clear that formation of nonenzymatic OxPLs during
chronic inflammation is an uncontrolled event, originating a
diverse range of different OxPLs species. On the other hand,
enzymatic formation of OxPLs is tightly regulated, involv-
ing receptors and signaling intermediates.
Although significant progress has been made in under-
standing the formation and function of a number of different
esterified PLs, more work is still needed; in particular, a
better understanding of the formation, regulation and, and
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interactions of OxPLs in disease would provide insights
into the function of lipid mediators, potentially leading
to new strategies for prevention and treatment of ath-
erosclerosis, thrombosis, cancer, and other related disor-
ders. In the future, OxPLs may also be used as valuable
biomarkers of inflammation, helping in the therapeutic
diagnosis.
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